Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401


NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Link:
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

Related Posts